EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety Assessment of Glucagon‐Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations

Zhenhan Li iD, Jun Huang, Sha Zhou, Yongan Luan, Huang Xie, Zhongpei Chen, Juan Xu iD, Jun Qian iD

Journal of Diabetes Research · 2026-01 · 2026 (1)

DOI: 10.1155/jdr/8893769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Research, online erschienen am 20.03.2026. Verfasst von Zhenhan Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Adverse Drug Reaction Reporting Systems, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Project of Chongqing Municipal Technological Innovation and Application Development Special Fund, Chongqing Medical Youth Top Talent Project, Chongqing Municipal Science and Health Joint Medical Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GLP‐1 receptor agonists (GLP‐1RAs) are extensively used in treating Type 2 diabetes due to their therapeutic benefits. However, clinical reports have highlighted adverse events, particularly the underexplored association with tumor development. This study investigates GLP‐1RA–related adverse events, focusing on tumorigenic risks, using data from the FDA Adverse Event Reporting System (FAERS). FAERS data from Q1 2005 to Q4 2023 were analyzed using the proportional reporting ratio (PRR) method to identify GLP‐1RA–associated adverse events. Detailed analyses examined event distribution across genders, ages, and body weights, with an emphasis on tumor‐related risks in vulnerable subpopulations. A total of 195,250 GLP‐1RA–related adverse event reports were identified, spanning 25 system organ classes (SOCs). The most reported SOCs were gastrointestinal disorders ( n = 110,451, PRR 2.44), investigative findings ( n = 80,126, PRR 2.46), and metabolism and nutrition disorders ( n = 25,236, PRR 2.21). Notably, 7457 cases involved benign, malignant, and unspecified tumors (PRR 0.5). Further analysis revealed that the risk of GLP‐1RA–associated tumorigenesis varied by age, sex, and weight, suggesting that tumorigenesis risk differed in specific subpopulations. These findings underscore the need for vigilance regarding GLP‐1RA–related adverse events, particularly tumor risks in specific subgroups. Clinicians should consider patient‐specific factors, such as age, gender, and body weight, to ensure safe and effective GLP‐1RAs therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsAdverse Drug Reaction Reporting SystemsDiabetes Mellitus, Type 2Hypoglycemic AgentsNeoplasmsCarcinogenesisHumansFemaleMaleMiddle AgedUnited StatesAdultDatabases, FactualAgedRisk AssessmentAdolescentRisk FactorsGlucagon-Like Peptide-1 ReceptorYoung AdultUnited States Food and Drug AdministrationChild

Stichwörter der Autor:innen

FAERSadverse drug eventsglucagon-like peptide 1 receptor agonistsreal-world data analysistumor-related risks

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Department of Endocrinology, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China.
  • Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing Medical University, Chongqing, China, cqmu.edu.cn.
  • Department of Cardiology, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, China, tongji.edu.cn.

ORCID-Profile: Zhenhan Li, Juan Xu, Jun Qian

Förderung

  • Key Project of Chongqing Municipal Technological Innovation and Application Development Special Fund
  • Chongqing Medical Youth Top Talent Project
  • Chongqing Municipal Science and Health Joint Medical Research Project
  • 4th Young Talent Project of Chongqing Traditional Chinese Medicine Hospital
  • Clinical Research Project of Tongji Hospital of Tongji University
  • Chongqing Postdoctoral Innovative Talents Support Program Fund

Zitieren

APA

Li, Z., Huang, J., Zhou, S., Luan, Y., Xie, H., Chen, Z., Xu, J., & Qian, J. (2026). Safety Assessment of Glucagon‐Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations. Journal of Diabetes Research, 2026(1). https://doi.org/10.1155/jdr/8893769

Vancouver

Li Z, Huang J, Zhou S, Luan Y, Xie H, Chen Z, et al. Safety Assessment of Glucagon‐Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations. Journal of Diabetes Research. 2026;2026(1). doi:10.1155/jdr/8893769

BibTeX
@article{Li2026,
  author = {Li, Zhenhan and Huang, Jun and Zhou, Sha and Luan, Yongan and Xie, Huang and Chen, Zhongpei and Xu, Juan and Qian, Jun},
  title = {Safety Assessment of Glucagon‐Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations},
  journal = {Journal of Diabetes Research},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jdr/8893769}
}
Kostenlos starten →